CVS refused to cover Yeztugo, Gilead’s $28,000-a-year injectable PrEP, preventing patients from accessing the HIV prevention ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

The EC approved lenacapavir, GILD’s twice-yearly injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

On Friday, the U.S. District Court for the District of Maryland paused several parts of a health insurance exchange enrollment and eligibility rule that was set to take effect today. The court agreed ...

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are ...

Gilead exceeded market expectations in the second quarter, reporting earnings per share of $2.01 on revenue of $7.08 billion. Profitability metrics impressed with a 21.86% margin and a return on ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...